RBC Capital analyst Conor McNamara initiated coverage of Natera (NTRA) with an Outperform rating and $251 price target The firm says Natera is the market leader in non-invasive prenatal testing and cancer screening with multiple approved and developing tests. The company also offers tests in organ transplant, and plans to bring cancer tests to market for early cancer screening and selection, the analyst tells investors in a research note. RBC believes Natera technology and innovation “puts it ahead of the curve” in these cancer testing opportunities.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera enrolls first patients in HEROES clinical trial Metastatic HER2+ BC
- Natera price target raised to $185 from $176 at Morgan Stanley
- Natera’s Strong Financial Performance and Growth Potential Reinforce Buy Rating
- USPTO issues Natera new patent related to testing of ctDNA
- Natera price target raised to $205 from $200 at Piper Sandler